YOUR SEARCH FOR Text 211 RESULTS
131 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2024 First Quarter Financial Results and …
132 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2024 Second Quarter Financial Results and …
133 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2024 Third Quarter Financial Results and …
134 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… … Incyte Reports 2024 Fourth Quarter and Year-End Financial …
135 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2025 First Quarter Financial Results and …
136 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2025 Second Quarter Financial Results and …
137 of Total
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatm
… Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatm …
138 of Total
The Unseen Journey Brings to Life the Impact of MPN Symptoms on Patients’ Lives | Incyte Stories
… March 21, 2024 The Unseen Journey Brings to Life the Impact of MPN Symptoms on Patients’ Lives For people living with myeloproliferative …
139 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… … Incyte Reports 2021 Fourth Quarter and Year-End Financial …
140 of Total
Privacy Policy | Incyte.com
… Policy Last Updated: January 7, 2026 Incyte Corporation (including its affiliates in its … laws. However, no Internet transmission is ever 100% secure, so we cannot guarantee the security …